148 related articles for article (PubMed ID: 15957243)
41. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma.
Hara T; Tsurumi H; Takemura M; Goto H; Yamada T; Sawada M; Takahashi T; Moriwaki H
Am J Hematol; 2000 Aug; 64(4):257-61. PubMed ID: 10911377
[TBL] [Abstract][Full Text] [Related]
42. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma.
Fischer M; Bijman M; Molin D; Cormont F; Uyttenhove C; van Snick J; Sundström C; Enblad G; Nilsson G
Leukemia; 2003 Dec; 17(12):2513-6. PubMed ID: 14562126
[TBL] [Abstract][Full Text] [Related]
43. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.
Papageorgiou A; Ziogas DC; Mavragani CP; Zintzaras E; Tzioufas AG; Moutsopoulos HM; Voulgarelis M
PLoS One; 2015; 10(2):e0116189. PubMed ID: 25723713
[TBL] [Abstract][Full Text] [Related]
44. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
[TBL] [Abstract][Full Text] [Related]
45. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
[TBL] [Abstract][Full Text] [Related]
46. High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma.
Salgami EV; Efstathiou SP; Vlachakis V; Sekara EV; Syrigos KN; Roussou PP
Haematologia (Budap); 2002; 32(4):377-87. PubMed ID: 12803112
[TBL] [Abstract][Full Text] [Related]
47. [Analysis for clinicopathological features, therapy and prognosis of 30 elderly patients with non-Hodgkin's lymphoma].
Wang HT; Yang B; Cai LL; Ran HH; Zhang WY; Zhu HL; Yang Y; Li SX; Fan H; Chi XH; Yu RL; Zhang F; Li BL; Lin J; Zhai B; Yao SQ; Lu XC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1464-70. PubMed ID: 24370030
[TBL] [Abstract][Full Text] [Related]
48. Prognostic markers in malignant lymphoma: an analysis of 1,198 patients treated at a single centre.
Low SE; Horsman JM; Hancock H; Walters SJ; Hancock BW
Int J Oncol; 2001 Dec; 19(6):1203-9. PubMed ID: 11713590
[TBL] [Abstract][Full Text] [Related]
49. Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin's lymphoma.
Lu T; Liu Y; Yu S; Yin C; Li P; Ye J; Ma D; Ji C
Oncotarget; 2016 Aug; 7(35):56574-56583. PubMed ID: 27489357
[TBL] [Abstract][Full Text] [Related]
50. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
[TBL] [Abstract][Full Text] [Related]
51. Increased Cytokine Levels Assist in the Diagnosis of Respiratory Bacterial Infections or Concurrent Bacteremia in Patients With Non-Hodgkin's Lymphoma.
Zhang L; Zhang J; He H; Ling X; Li F; Yang Z; Zhao J; Li H; Yang T; Zhao S; Shi K; Guan X; Zhao R; Li Z
Front Cell Infect Microbiol; 2022; 12():860526. PubMed ID: 35463642
[TBL] [Abstract][Full Text] [Related]
52. Increased soluble serum HLA class I antigens in patients with lymphoma.
Nocito M; Montalbán C; González-Porque P; Villar LM
Hum Immunol; 1997 Dec; 58(2):106-11. PubMed ID: 9475339
[TBL] [Abstract][Full Text] [Related]
53. [Clinical and prognostic analysis of 101 cases of primary gastrointestinal non-Hodgkin's lymphoma].
Song LN; Cen XN; Ou JP; Liang ZY; Qiu ZX; Wang WS; Xu WL; Li Y; Wang MJ; Dong YJ; Yin Y; Sun YH; Liu W; Wang Q; Wang LH; Wang Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):387-91. PubMed ID: 23628038
[TBL] [Abstract][Full Text] [Related]
54. Age-related prognostic factor analysis in non-Hodgkin's lymphoma.
Maksymiuk AW; Haines C; Tan LK; Skinnider LF
Can J Oncol; 1996 Jun; 6(1):435-42. PubMed ID: 8853516
[TBL] [Abstract][Full Text] [Related]
55. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma.
Stasi R; Stipa E; Masi M; Oliva F; Sciarra A; Perrotti A; Zaccari G; Papa G
Thromb Haemost; 1993 Oct; 70(4):568-72. PubMed ID: 8115979
[TBL] [Abstract][Full Text] [Related]
56. Cytokine deregulation in hematological malignancies: clinical and biological implications.
Kurzrock R
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2581-4. PubMed ID: 9815659
[TBL] [Abstract][Full Text] [Related]
57. Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma.
Feldmann G; Nischalke HD; Nattermann J; Banas B; Berg T; Teschendorf C; Schmiegel W; Dührsen U; Halangk J; Iwan A; Sauerbruch T; Caselmann WH; Spengler U
Clin Cancer Res; 2006 Aug; 12(15):4491-8. PubMed ID: 16899594
[TBL] [Abstract][Full Text] [Related]
58. Clinical and prognostic analysis of 125 cases of non-Hodgkin's lymphoma.
Liu L; Zhang M; Zou P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):547-50. PubMed ID: 18549626
[TBL] [Abstract][Full Text] [Related]
59. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
[TBL] [Abstract][Full Text] [Related]
60. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
